<DOC>
	<DOCNO>NCT00462007</DOCNO>
	<brief_summary>An open , non-randomised , multinational , multicentre direct switch study levodopa-treated Parkinson 's disease patient suffer early wearing-off Parkinson 's disease . The study consist 2 consecutive period : screening period study treatment period . Duration study 8 week subject . The study treatment dosage determine subject 's current , separately administer standard levodopa/DDCI treatment ( 3-4 dos per day , maximum total daily dose 600 mg levodopa ) switch equivalent dose Stalevo® without change number dos per day . The levodopa daily dose Stalevo® treatment may adjust accord study subject 's clinical response .</brief_summary>
	<brief_title>Study Evaluate Initiation Stalevo Early Wearing-off</brief_title>
	<detailed_description>See 'Brief summary ' .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Subjects idiopathic Parkinson 's disease early wearingoff symptom treat standard levodopa/DDCI treatment Age &gt; 35 year Hoehn Yahr stage 13 perform 'ON'stage At least 1 symptom identify WOQ9 Dosing frequency 34 dos standardrelease levodopa/DDCI ( maximum total daily dose 600 mg levodopa ) Atypical symptomatic Parkinson 's disease Unpredictable OFFperiods Any peakdose dyskinesia . 'OFF'state dystonia allow Use rescue medication treat symptom 'OFF'state . 1 dose soluble levodopa/DDCI allow . Concomitant treatment nonselective monoamine oxidase ( MAO ) inhibitor simultaneous use high recommended dos MAOA MAOB inhibitor ( selegiline 10 mg rasagiline 1 mg allow ) use apomorphine .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>